Takashi Tokunaga, Akihiro Tomita, Keiki Sugimoto, Kazuyuki Shimada, Chisako Iriyama, Tatsuya Hirose, Mizuho Shirahata-Adachi, Yasuhiro Suzuki, Hiroki Mizuno, Hitoshi Kiyoi, Naoko Asano, Shigeo Nakamura, Tomohiro Kinoshita and Tomoki Naoe De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity Cancer Science 105
Article first published online: 22 DEC 2013 | DOI: 10.1111/cas.12307
Some de novo DLBCL show CD20 IHC(+)/FCM(−) phenotype. Lower CD20 mRNA expression is closely related to this phenomenon. Since partial effectiveness of rituximab was confirmed in CDC assay in vitro, rituximab utilization for those patients may be still recommended.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field